Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBS101
- Development stage
- Preclinical
- Lead developer
- CellmAbs
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CBS101 (also referred to as CB101) is a preclinical-stage monoclonal antibody developed by CellmAbs. It is designed to target cancer-specific glycans, which are post-translational modifications of proteins that are aberrantly expressed on the surface of various solid tumors but absent or restricted in healthy tissues. By binding to these tumor-associated carbohydrate antigens (TACAs), such as the Tn antigen, CBS101 aims to provide a highly selective therapeutic approach for oncology, potentially minimizing off-target effects. The program is currently in preclinical development for the treatment of solid tumors.
Beyond the preview
Go deeper on CBS101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBS101.